Metastatic Renal Cell Carcinoma - Pipeline Insight, 2024

Metastatic Renal Cell Carcinoma - Pipeline Insight, 2024

DelveInsight’s, “Metastatic Renal Cell Carcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Metastatic Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Metastatic Renal Cell Carcinoma Understanding

Metastatic Renal Cell Carcinoma: Overview

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 85% of neoplasms arising from the kidney. Renal cell carcinoma may remain clinically occult for most of its course. Only 10% of patients present with the classic triad of flank pain, hematuria, and flank mass. Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases. The clinical management of patients with metastatic RCC is complicated by the lack of significant efficacy from available therapies. Common sites of metastases include the lung, liver, bone, brain, and adrenal gland, with case reports detailing the capacity of RCC to appear almost anywhere in the body. More than one organ system is often involved in the metastatic process. Metastases may be found at diagnosis or at some interval after nephrectomy. Approximately 20% to 50% of patients will eventually develop metastatic disease after nephrectomy. A shorter interval between nephrectomy and the development of metastases is associated with a poorer prognosis. Patients with metastatic RCC face a dismal prognosis, with a median survival time of only 6 to 12 months and a 2-year survival rate of 10% to 20%.

""Metastatic Renal Cell Carcinoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Metastatic Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Metastatic Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Metastatic Renal Cell Carcinoma.
• In the coming years, the Metastatic Renal Cell Carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Metastatic Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Metastatic Renal Cell Carcinoma treatment market. Several potential therapies for Metastatic Renal Cell Carcinoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Metastatic Renal Cell Carcinoma market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Metastatic Renal Cell Carcinoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Metastatic Renal Cell Carcinoma Emerging Drugs Chapters

This segment of the Metastatic Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic Renal Cell Carcinoma Emerging Drugs

• Olaparib: AstraZeneca

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014. Currently, it is in Phase II stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.

• Atezolizumab: Genentech

Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. Currently, it is in Phase III stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.

• TP-1454: Sumitomo Dainippon Pharma

TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.

Further product details are provided in the report……..

Metastatic Renal Cell Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Metastatic Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Metastatic Renal Cell Carcinoma

There are approx. 40+ key companies which are developing the therapies for Metastatic Renal Cell Carcinoma. The companies which have their Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic Renal Cell Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Renal Cell Carcinoma drugs.

Metastatic Renal Cell Carcinoma Report Insights

• Metastatic Renal Cell Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Metastatic Renal Cell Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Metastatic Renal Cell Carcinoma drugs?
• How many Metastatic Renal Cell Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Renal Cell Carcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Renal Cell Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metastatic Renal Cell Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Genentech
• Sumitomo Dainippon Pharma
• Allogene Therapeutics
• Nektar Therapeutics
• Eli Lilly and Company
• Xynomic Pharmaceuticals
• AnewPharma
• HUTCHMED
• MedImmune
• Incyte Corporation
• NiKang Therapeutics
• OncoC4, Inc.
• Nanobiotix
• Aravive
• Mirati Therapeutics Inc.
• BeiGene
• Shanghai PerHum Therapeutics Co., Ltd.
• Akeso Biopharma
• Novartis Pharmaceuticals
• Vaccibody
• SillaJen, Inc.
• Chongqing Precision Biotech Co., Ltd
• Infinity Pharmaceuticals, Inc.
• SOTIO Biotech AG
• Pfizer
• Peloton Therapeutics, Inc.
• NeoTX Therapeutics Ltd.

Key Products

• Olaparib
• Atezolizumab
• TP-1454
• ALLO 316
• SO-C101
• VB10.NEO
• PF-07209960
• INCB001158
• IPI-549
• DSP-7888
• Belzutifan
• CD70 CAR-T
• Sitravatinib
• Pexastimogene Devacirepvec
• Gevokizumab
• AK104
• CCT301
• Pamiparib
• ONC-392
• Batiraxcept
• AZD6738
• NBTXR3
• NKT2152
• Bempegaldesleukin
• Abemaciclib
• Abexinostat
• CM082
• TP-1454
• Savolitinib
• Epacadostat
• MEDI4736